THE CANNABIS CONVERSATION - EPISODE #79
Investigating CBN with Alan Ridgeway, Co-Founder and CEO at FloraWorks
This week we’re joined by Alan Ridgeway, Co-Founder and CEO at FloraWorks – a Canadian hemp refinement laboratory offering specialized cannabinoid formulations. Together, we explore one of the ‘minor’ cannabinoids – CBN. We take a look at its incredible therapeutic properties, mechanism of action, and its potential as a market disruptor.
Seven Intrinsic Questions With CEO Of FloraWorks: Alan Ridgeway
“I truly believe this molecule (CBN) has the potential to be an important wellness product that can help a lot of people and I’m extremely excited to work with the team we have at FloraWorks to bring it to market.”
– Alan Ridgeway
Also Known as “The Sleep Cannabinoid”, Cannabinol (CBN) Is Now Available in Commercial Quantities
This rare cannabinoid is taking the wellness and CBD markets by storm as new research and anecdotal evidence expands.
PORTLAND BUSINESS JOURNAL
This Oregon company is betting on the next next big thing in hemp.
Milwaukie startup thinks it’s cracked the code on an elusive cannabinoid, CBN.
© 2020 FloraWorks. All Rights Reserved.